Featured Clinical Trials

  • Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma (NCT03150329).
PI email: Alex Herrera
  • Phase 1 Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma (NCT03013933).
PI email: Robert Chen
  • Phase 1/2 Trial of Durvalumab (MEDI4736) when Given as a Single Agent or in Combination with Lenalidomide in Patients with Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma (NCT03011814).
  • Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantion in Patients with Mature T-Cell Non-Hodgkin Lymphoma: the aTAC-BEAM Regimen (NCT02342782).
PI email: Jasmine Zain
  • Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (NCT02631044).
PI email: Tanya Siddiqi